Loading company…
Pan Cancer T develops TCR-T cell therapies for cancer treatment.
Founded in 2020 and based in Rotterdam, Netherlands, Pan Cancer T develops engineered T cell therapies designed to target cancer antigens. In July 2024, it raised EUR 4.25 million in Seed funding led by InnovationQuarter, with Erasmus MC Biomedical Fund, Swanbridge Capital, Thuja Capital and Van Herk Group. The funding will support preclinical work on its lead product, PCT1:CO-STIM, and CMC activities.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in